reviewsShould progression-free survival be the primary measure of efficacy for advanced NSCLC therapy?
Under an Elsevier user license
open archive
Keywords
clinical trials
end point determination
non-small-cell lung cancer
NSCLC
overall survival
progression-free survival
Cited by (0)
Copyright © 2010 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved.